Case Description: A 67-year-old female patient with HER2-positive OCCC was admitted to our hospital because of
fever, who benefited greatly from treatment with
pyrotinib, an irreversible HER2 antagonist conditionally approved for patients with advanced or metastatic HER2-positive
breast cancer in China. The patient, who had previously been diagnosed with stage IA OCCC [according to the International Federation of Gynecology and Obstetrics (FIGO)] and undergone radical surgery with standard
adjuvant chemotherapy on May 15, 2017, was diagnosed with HER2-positive OCCC at FIGO stage IIIC. She was treated with oral
pyrotinib (400 mg/day in 21-day cycles) starting on November 27, 2018. Imaging assessments were conducted every 2 to 4 treatment cycles. Best response by response evaluation criteria in solid tumors (RECIST) 1.1 were partial response. However, on March 30, 2021, the patient was assessed using contrast-enhance CT and found to have progressive disease with liver
metastases. Subsequently, on April 26, 2021, the patient underwent liver microwave ablation and ultrasound-guided liver biopsy. The immunohistochemistry results of the liver biopsy showed the origin of the disease to be ovarian. Therefore, the disease was identified as HER2-positive OCCC at FIGO stage IVB.
Conclusions: Progression-free survival (PFS) in second-line
chemotherapy for patients with recurrent OC ranges from 3.8 to 11.3 months. In the case of this patient, treatment with
pyrotinib yielded a PFS of 28 months, which was a promising result for the use of
pyrotinib in treating HER2-positive OC.